Research programme: I kappa beta kinase inhibitors - Astellas Pharma
Alternative Names: AS 1950930Latest Information Update: 16 Jul 2016
At a glance
- Originator Astellas Pharma
- Class Cyclopropanes; Phenols; Piperidines; Pyrimidines
- Mechanism of Action I-kappa B kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Japan
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Japan
- 04 Sep 2008 Preclinical trials in Inflammation in Japan (unspecified route)